Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 78.3%

Neg 0% Neu 0% Pos 78.3%

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $39 to $40.